AI Analysis | Feedback

• Moderna for transdermal patches.
• Dexcom for drug-delivery patches.

AI Analysis | Feedback

• AVERSA™ Technology: A proprietary abuse-deterrent transdermal patch platform designed to prevent the tampering and misuse of opioid and other abuse-prone drugs.
• AVERSA™ Fentanyl Patch: A tamper-resistant transdermal fentanyl patch under development for the treatment of chronic pain, leveraging the AVERSA™ technology.

AI Analysis | Feedback

Nutriband Inc. (NTRB) is a pharmaceutical technology company that primarily sells its proprietary transdermal drug delivery systems and intellectual property to other companies (B2B model). Its business strategy involves developing products to proof-of-concept and then seeking strategic partners to license, commercialize, and distribute its technologies.

Its major customers and strategic partners, based on significant licensing agreements, include:

• Kindeva Drug Delivery L.P.: Kindeva is a private contract development and manufacturing organization (CDMO) specializing in transdermal patches. It holds exclusive worldwide rights for the development, manufacturing, and commercialization of certain transdermal products incorporating Nutriband's AVERSA™ abuse-deterrent technology.
• Neurim Pharmaceuticals (1991) Ltd.: Neurim is a private pharmaceutical company. It holds exclusive worldwide rights to develop, manufacture, and commercialize a melatonin transdermal patch product utilizing Nutriband's technology.

AI Analysis | Feedback

null

AI Analysis | Feedback

AI Analysis | Feedback

The public company Nutriband (symbol: NTRB) faces several key risks, primarily centered around its pharmaceutical product development and commercialization.

1. Regulatory Approval Risk: The most significant risk for Nutriband is its ability to obtain Federal Food and Drug Administration (FDA) approval for its lead product, the AVERSA™ Fentanyl patch, and other potential products. The company's business model and the commercial viability of its abuse-deterrent technology are highly dependent on successful regulatory clearance in the United States and other countries. There is no guarantee that Nutriband will obtain these necessary approvals.
2. Financing and Capital Risk: As an "undercapitalized developing company," Nutriband's operations and product development are subject to the risk of obtaining sufficient financing. The company needs capital to fund clinical testing, advance product development, and support its overall growth. The inability to secure adequate funding could impede its progress and long-term viability.
3. Commercialization and Market Adoption Risk: Even if Nutriband secures regulatory approval for its AVERSA™ Fentanyl patch, there remains a substantial risk associated with its successful commercialization and market adoption. Factors such as market acceptance, competition from existing or new products, and the company's ability to effectively market and distribute its products could significantly impact its revenue and profitability.

AI Analysis | Feedback

The clear emerging threat to Nutriband (NTRB) is the accelerating and sustained decline in overall opioid prescriptions, driven by tightening regulatory guidelines, public health initiatives, and the growing emphasis on non-opioid alternatives for pain management. This systemic market shift reduces the addressable market for all opioid products, including Nutriband's abuse-deterrent transdermal opioid patches, thereby limiting the growth and long-term viability of its core AVERS™ platform.

AI Analysis | Feedback

Nutriband Inc. (NTRB) operates primarily in the transdermal drug delivery sector, with a flagship focus on abuse-deterrent transdermal pharmaceutical products and a presence in consumer transdermal goods and contract manufacturing. The addressable markets for their main products and services are substantial:

• Global Transdermal Patches Market: The overall global transdermal patches market was valued at approximately USD 7.84 billion in 2024 and is projected to reach USD 11.50 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.90% during the forecast period. Another estimate places the market at USD 7.9 billion in 2023, expected to reach USD 12.5 billion by 2033, with a CAGR of 4.7% from 2024 to 2033. North America held a significant share of this market, accounting for 38.5% in 2024 and dominating with a 48.2% share (USD 3.8 billion) in 2023.

• Global Pain Relief Patches Market: A critical segment for Nutriband's abuse-deterrent opioid patches, the global pain relief patches market was valued at USD 3.9 billion in 2023 and is estimated to grow at a CAGR of 6.2% between 2024 and 2032, reaching USD 6.0 billion by 2032. Another report projects the global pain patch market to reach USD 12.87 billion by the end of 2034, growing at a CAGR of 8.1% from 2024. In 2023, the pain relief segment alone accounted for over 65.9% of the transdermal patch market. North America dominated the pain relief patches market, valued at around USD 1 billion in 2023 and expected to reach USD 1.8 billion by 2032, and is estimated to hold a 50% share in 2025.

• Abuse-Deterrent Opioid Patches (Specific to AVERSA™ Technology): Nutriband's lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal patch, has projected peak annual sales in the U.S. of USD 80 million to USD 200 million. Their second product in development, AVERSA™ Buprenorphine, is estimated to achieve USD 70 million to USD 130 million in peak annual sales.

• Global Vitamin Patches Market: For its consumer transdermal products, including vitamin and supplement patches, the global vitamin patches market was estimated at USD 206.8 million in 2024 and is projected to reach USD 532.1 million by 2030, exhibiting a robust CAGR of 16.1% from 2025 to 2030. North America was the largest revenue-generating market for vitamin patches in 2024, with the U.S. market specifically expected to grow at a CAGR of 15.2% from 2025 to 2030.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Nutriband (NTRB)

• Regulatory Approval and Commercialization of AVERSA Fentanyl: The company's lead product, AVERSA Fentanyl, an abuse-deterrent fentanyl patch, is a significant future revenue driver. Nutriband is actively progressing towards a New Drug Application (NDA) filing, with a scheduled Type C meeting with the FDA in September 2025. The NDA filing is expected to require only a single Phase 1 Human Abuse Potential study, bypassing the need for Phase 2 or 3 trials. Market analysis by Health Advances projects potential peak annual sales for AVERSA Fentanyl between $80 million and $200 million.
• Expansion of Kinesiology Tape Contract Manufacturing Services (Pocono Pharma): Nutriband is growing its kinesiology tape output through its subsidiary, Pocono Pharma. This expansion includes a focus on penetration pricing to secure a stronger foothold with major industry brands. Pocono-manufactured products are increasingly being rolled out into prominent national retail locations such as Target, Walmart, Walgreens, and CVS, contributing to a growing revenue stream.
• Development and Potential Launch of AVERSA Buprenorphine and other Transdermal Products: Beyond AVERSA Fentanyl, Nutriband is developing a portfolio of transdermal pharmaceutical products utilizing its AVERSA™ abuse-deterrent technology. AVERSA Buprenorphine is another product with significant market potential, estimated to reach up to $130 million in peak annual sales. The AVERSA™ technology can be incorporated into various transdermal patches to deter abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
• Strategic Partnerships for Product Development and Commercialization: Nutriband's formalized product development partnership with Kindeva Drug Delivery for AVERSA Fentanyl is a strategic move designed to advance its transdermal drug delivery solutions. This collaboration involves shared development costs in exchange for milestone payments, which is crucial for moving towards regulatory approval and eventual commercialization.

AI Analysis | Feedback

Share Repurchases

• Nutriband Inc. authorized a $1 million share buyback program on September 16, 2024.

Share Issuance

• In October 2021, Nutriband completed a public offering of 1,056,000 units at $6.25 per unit, generating gross proceeds of $6.6 million.
• As of July 25, 2024, the exercise of 457,795 warrants from the October 2021 IPO generated net proceeds of $2,942,970 for the company.
• An $8.4 million private placement was announced in April 2024, aimed at providing funding through the NDA filing for AVERSA Fentanyl.
• In July 2025, a 25% preferred stock dividend was declared, with preferred shares convertible to common stock upon FDA approval of AVERSA Fentanyl.

Inbound Investments

• No specific large investments made in the company by third-party strategic partners or private equity firms were identified within the last 3-5 years, beyond capital raised through public offerings and private placements.

Outbound Investments

• Nutriband completed the acquisition of Pocono Coated Products LLC's Transdermal and Health product manufacturing business for $7.5 million on August 31, 2020. The consideration for this acquisition included $6 million in common stock and a $1.5 million promissory note, and it expanded Nutriband's manufacturing capabilities.

Capital Expenditures

• Capital expenditures were approximately $52,282 in the most recent 12 months as of October 31, 2024 (or July 2025).
• For the fiscal year ended January 31, 2024, capital expenditures were $82,000.
• Capital expenditures were $79,000 for the fiscal year ended January 31, 2023, and $52,000 for the fiscal year ended January 31, 2022.